InvestorsHub Logo
Followers 2
Posts 2022
Boards Moderated 0
Alias Born 05/11/2017

Re: None

Wednesday, 06/12/2019 8:28:29 AM

Wednesday, June 12, 2019 8:28:29 AM

Post# of 108192
Interesting to note that 2 patients with metastatic colorectal cancer treated by NEO achieved stable disease (SD). This data must be compared with the Amgen/KRAS data for for the same indication. Looks like we are not doing worse than Amgen in this area. Let's see data for NSCLC patients. KRAS achieved PRs (5 out of 10).

KRAS: "The data in colorectal cancer were less promising. There were no partial responses here, and the best that Amgen could say was that 13 of 18 evaluable subjects achieved stable disease."
https://www.evaluate.com/vantage/articles/events/conferences/asco-2019-kras-chase-heats-amgen-data
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News